[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362501-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362501-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","metabolic-vulnerabilities-as-a-therapeutic-target-in-breast-cancer-review","Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer - Review","","Metabolic reprogramming is a defining feature of breast cancer, sustaining rapid tumor proliferation, survival under stress, and resistance to therapy. Core pathways—glycolysis, glutaminolysis, lipid metabolism, and one-carbon metabolism—support energy production, biosynthesis, membrane formation, and epigenetic and nucleotide regulation. Preclinical evidence suggests pathway inhibition can slow growth, yet metabolic plasticity, tumor heterogeneity, and toxicity risks in normal tissues require biomarker-driven strategies and rational combination therapies. The review summarizes pathway roles in progression, prognosis, and key enzyme targets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/metabolic-vulnerabilities-as-a-therapeutic-target-in-breast-cancer-review/362501/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/metabolic-vulnerabilities-as-a-therapeutic-target-in-breast-cancer-review/362501.png","ImageObject",300,407,{"name":42,"@type":43},"Kyle","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is metabolism considered a therapeutic target in breast cancer?","Question",{"text":63,"@type":64},"Breast cancer cells reprogram nutrient use to sustain proliferation, survival under stress, and resistance to therapy. These adaptations create metabolic vulnerabilities that can be exploited by inhibiting key pathways.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which metabolic pathways are highlighted as central to breast cancer growth?",{"text":68,"@type":64},"The review emphasizes glycolysis, glutaminolysis, lipid metabolism, and one-carbon metabolism. It also discusses the TCA cycle, lipid/fatty acid synthesis, and serine- and glutamine-related metabolism as contributors to tumor demands.",{"name":70,"@type":61,"acceptedAnswer":71},"What challenges limit direct translation of pathway inhibition to treatments?",{"text":72,"@type":64},"Metabolic plasticity and tumor heterogeneity can reduce efficacy, while potential toxicity in normal tissues is a concern. These issues motivate biomarker-driven approaches and rational combination therapies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362501,1790574668,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Review  \nMetabolic Vulnerabilities as a Therapeutic Target in Breast Cancer  \nSabrina Guo 1,2 and Christina L. Addison 1,2,3, *  \nReceived: 12 January 2026  \nRevised: 14 February 2026  \nAccepted: 17 February 2026  \nPublished: 23 February 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Cancer Research Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada; [sguo@ohri.ca](sguo@ohri.ca)  \n2 Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8L1, Canada  \n3 Department of Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8L1, Canada  \n* Correspondence: caddison@ohri.ca  \nSimple Summary  \nBreast cancer cells change the way they use nutrients to grow and survive, which makes their metabolism an important area for new treatments. These cells often rely on specific pathways, such as those that process sugar, amino acids, and fats, to produce energy and build essential components. Recent research shows that blocking these pathways can slow cancer growth and make existing treatments more effective. However, better understanding of these metabolic changes and their roles in different breast cancer subtypes could lead to more personalized therapies and improve outcomes for patients in the future.  \nAbstract  \nMetabolic reprogramming is a defining feature of breast cancer, enabling tumor cells to sustain rapid proliferation, survive under stress, and resist therapy. Key pathways including glycolysis, glutaminolysis, lipid metabolism, and one-carbon metabolism, play central roles in meeting the energetic and biosynthetic demands of malignant cells. Enhanced glycolytic flux supports ATP generation and lactate production, while glutamine metabolism fuels the tricarboxylic acid cycle and provides nitrogen for nucleotide synthesis. Lipid metabolic pathways, particularly fatty acid synthesis, contribute to membrane biogenesis and signaling, and one-carbon metabolism driven by serine and glycine supplies methyl groups for epigenetic regulation and nucleotide production. These metabolic adaptations not only promote tumor growth but also create vulnerabilities that can be exploited therapeutically. Inhibiting these pathways has shown promise in preclinical models; however, challenges such as metabolic plasticity, tumor heterogeneity, and potential toxicity in normal tissues underscore the need for biomarker-driven strategies and rational combination therapies. Herein, we describe current knowledge of the role of these pathways in breast cancer progression, highlighting the role of key enzymes in promoting breast cancer tumor cell growth and in breast cancer prognoses.  \nKeywords: breast cancer; metabolism; prognosis; tumor growth; glycolysis; pentose phosphate pathway; serine biosynthesis; glutaminolysis; fatty acids; TCA cycle  \n1. Introduction  \nBreast cancer is the leading cause of cancer and cancer death in women, with 1.9 million new cases and 495,000 deaths globally in 2022 [1] . Despite advancements in diagnosis and therapy, mortality rates remain high, largely due to treatment resistance [2] . As a result, researchers are increasingly exploring alternative features driving cancer progression and  \ndrug resistance to identify new vulnerabilities that could be targeted for more effective breast cancer treatment.  \nIn recent years, altered cancer metabolism has emerged as a cancer driver and is now recognized as a ‘hallmark’ of cancer [3] . Oncogene over-expression (e.g. Myc, PI3K/Akt, KRAS, and Her2), or loss of key tumor suppressors (e.g. TP53 and BRCA1) can lead to altered metabolism that support tumor cell growth and survival [4–9] . These genetic alterations converge on key metabolic pathways, including glycolysis (affected by e.g. MYC, BRCA, KRAS), the tricarboxylic acid ","cbCaicmDDUbneyIb","https://ap.wps.com/l/cbCaicmDDUbneyIb","pdf",1563458,34,"English","# Abstract\n# Keywords\n# 1. Introduction\n## Breast cancer burden and treatment resistance\n## Cancer metabolism as a hallmark and genetic drivers\n## Metabolic reprogramming in breast cancer progression and resistance\n# Figure 1. Metabolic pathways driving breast cancer growth","[{\"question\":\"Why is metabolism considered a therapeutic target in breast cancer?\",\"answer\":\"Breast cancer cells reprogram nutrient use to sustain proliferation, survival under stress, and resistance to therapy. These adaptations create metabolic vulnerabilities that can be exploited by inhibiting key pathways.\"},{\"question\":\"Which metabolic pathways are highlighted as central to breast cancer growth?\",\"answer\":\"The review emphasizes glycolysis, glutaminolysis, lipid metabolism, and one-carbon metabolism. It also discusses the TCA cycle, lipid/fatty acid synthesis, and serine- and glutamine-related metabolism as contributors to tumor demands.\"},{\"question\":\"What challenges limit direct translation of pathway inhibition to treatments?\",\"answer\":\"Metabolic plasticity and tumor heterogeneity can reduce efficacy, while potential toxicity in normal tissues is a concern. These issues motivate biomarker-driven approaches and rational combination therapies.\"}]","Metabolic Vulnerabilities as a Therapeutic Target in Breast Cancer - Review | PDF",1790147990,86,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1c80b0d288db52daa37a2138280ec4e1.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7949fbfeecc01916b56101034b8cc8e5.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/700461a6f43518997c01760515aa2262.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3eaecb334190d9aeb4c41d0bbceb7bcc.webp",980,1385]